Carver Kyle 4

What Happened
Kyle Carver, Chief Financial Officer of Evommune, Inc. (EVMN), sold 18,175 shares in an open-market transaction on 2026-05-28 for a weighted average price of $22.84, totaling about $415,117. On the same date he exercised 15,000 optioned shares at $2.99 per share (cost $44,850) resulting in an acquisition of those shares. The filing also reports a separate line showing 15,000 shares disposed at $0 (listed as a derivative disposition).

Key Details

• Transaction date: 2026-05-28 (filed 2026-06-01). Filing appears timely (within the required reporting window).
• Sale: 18,175 shares sold, weighted avg price $22.84, total proceeds ≈ $415,117. Reported sale prices ranged from $22.50 to $23.42. (See footnote offering breakdown on request.)
• Exercise/Acquisition: 15,000 shares acquired via exercise at $2.99/share for $44,850.
• Derivative disposition: 15,000 shares listed as disposed at $0 (reported as a derivative entry). Such zero-priced disposals commonly reflect net-share settlement or withholding associated with option exercises.
• Shares owned after transaction: Not specified in the provided filing data.
• Footnotes: F1 — sale was pursuant to a Rule 10b5-1 trading plan adopted 2026-02-26; F2 — sale price shown is a weighted average (range $22.50–$23.42); F3 — option vesting schedule noted (1/4 after one year, then monthly over 36 months).

Context

• The activity combines an option exercise (acquisition) with an open-market sale under a pre-established 10b5-1 plan; sales executed under such plans are often routine and pre-scheduled rather than ad hoc signals of sentiment.
• For option exercises, it's common to see some shares withheld or surrendered for taxes or to cover exercise costs — the zero-dollar derivative disposition likely reflects that settlement mechanism.
• This filing is of interest to investors watching insider liquidity and option exercises, but it does not by itself indicate the insider’s view of the company’s long-term prospects.